JOP20200126A1 - طرق استخدام وتركيبات تحتوي على دولاجلوتيد - Google Patents

طرق استخدام وتركيبات تحتوي على دولاجلوتيد

Info

Publication number
JOP20200126A1
JOP20200126A1 JOP/2020/0126A JOP20200126A JOP20200126A1 JO P20200126 A1 JOP20200126 A1 JO P20200126A1 JO P20200126 A JOP20200126 A JO P20200126A JO P20200126 A1 JOP20200126 A1 JO P20200126A1
Authority
JO
Jordan
Prior art keywords
methods
compositions containing
dulaglutide
containing dulaglutide
doses
Prior art date
Application number
JOP/2020/0126A
Other languages
English (en)
Inventor
David Bradley Woodward
Zvonko Milicevic
David Andrew Cox
Andrew Gordon Werner
Lai San Tham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200126A1 publication Critical patent/JOP20200126A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

يتعلق الاختراع الحالي بطرق استخدام جرعات جديدة من دولاجلوتيد وتركيبات تحتوي على هذه الجرعات المرتفعة من دولاجلوتيد.
JOP/2020/0126A 2017-11-21 2018-11-13 طرق استخدام وتركيبات تحتوي على دولاجلوتيد JOP20200126A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (1)

Publication Number Publication Date
JOP20200126A1 true JOP20200126A1 (ar) 2020-05-21

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0126A JOP20200126A1 (ar) 2017-11-21 2018-11-13 طرق استخدام وتركيبات تحتوي على دولاجلوتيد

Country Status (20)

Country Link
US (1) US11576950B2 (ar)
EP (1) EP3713593A2 (ar)
JP (3) JP7221956B2 (ar)
KR (2) KR102589234B1 (ar)
CN (1) CN111356472A (ar)
AU (2) AU2018372709B2 (ar)
BR (1) BR112020007817A2 (ar)
CA (1) CA3082625A1 (ar)
CL (1) CL2020001252A1 (ar)
CR (1) CR20200202A (ar)
DO (1) DOP2020000104A (ar)
EA (1) EA202090971A1 (ar)
EC (1) ECSP20026436A (ar)
IL (1) IL274563B2 (ar)
JO (1) JOP20200126A1 (ar)
MA (1) MA50798A (ar)
MX (1) MX2020005231A (ar)
SG (1) SG11202003687RA (ar)
UA (1) UA127588C2 (ar)
WO (1) WO2019103875A2 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021154591A1 (en) * 2020-01-30 2021-08-05 Eli Lilly And Company Therapeutic uses of dulaglutide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
AU2005319432A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company GLP-1 analog fusion protein formulations
WO2009009562A2 (en) * 2007-07-10 2009-01-15 Eli Lilly And Company Glp-1-fc fusion protein formulation
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PL3630164T3 (pl) 2017-06-01 2024-01-29 Eli Lilly And Company Dulaglutyd do leczenia przewlekłej choroby nerek

Also Published As

Publication number Publication date
KR102589234B1 (ko) 2023-10-16
WO2019103875A2 (en) 2019-05-31
DOP2020000104A (es) 2020-08-31
US20200330558A1 (en) 2020-10-22
IL274563A (en) 2020-06-30
JP7221956B2 (ja) 2023-02-14
CR20200202A (es) 2020-08-20
CL2020001252A1 (es) 2020-10-30
JP2021502379A (ja) 2021-01-28
JP2022062153A (ja) 2022-04-19
AU2018372709B2 (en) 2022-04-28
CN111356472A (zh) 2020-06-30
IL274563B1 (en) 2023-08-01
EA202090971A1 (ru) 2020-08-07
JP2024056908A (ja) 2024-04-23
ECSP20026436A (es) 2020-06-30
EP3713593A2 (en) 2020-09-30
MA50798A (fr) 2020-09-30
US11576950B2 (en) 2023-02-14
AU2022203372A1 (en) 2022-06-09
UA127588C2 (uk) 2023-10-25
SG11202003687RA (en) 2020-06-29
IL274563B2 (en) 2023-12-01
MX2020005231A (es) 2020-08-24
CA3082625A1 (en) 2019-05-31
KR20220146656A (ko) 2022-11-01
AU2018372709A1 (en) 2020-05-14
NZ763815A (en) 2023-11-24
BR112020007817A2 (pt) 2020-10-06
KR20200076705A (ko) 2020-06-29
WO2019103875A3 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2019015744A (es) Composiciones farmaceuticas.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
PH12019502469A1 (en) Novel fragrance compositions and products with mood enhancing effects
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
MX2021006977A (es) Anellosomas y metodos de uso.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MX2022010827A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
JOP20200126A1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
NZ721832A (en) Solid forms of tenofovir
PH12017501897A1 (en) 2-thiopyrimidinones
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
MX2020003763A (es) Composiciones de flumioxazina y metodos para usar las mismas.